RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept
  • Home
  • Impact
  • Publications
  • Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Mulligan, G., Lichter, D. I., & Schu, M. (2014). Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood, 123(5), 632-639.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

"Show Me the Energy Costs"
Article

Urinary cadmium and stroke - a case-cohort study in Danish never-smokers
Article

Integrated energy-water-land nexus planning in the Colorado River Basin (Argentina)
Chapter

Indonesia